Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 214-221

  May, Theodor W ^a,d   Boor, Rainer ^b   Rambeck, Bernhard ^a   Jürgens, Uwe ^a   Korn Merker, Elisabeth ^c   Brandt, Christian ^c  

^a Society for Epilepsy Research   (Germany)

^b Northern German Epilepsy Center   (Germany)

^c EPILEPSY CENTER BETHEL   (Germany)

^d Pharmakologisches Labor   (Germany)

Author keywords

age; antiepileptic drugs; clearance; concentration to dose relationship; drug interactions; rufinamide; therapeutic drug monitoring

Indexed keywords

BROMIDE; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; STIRIPENTOL; SULTIAME; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG POTENTIATION; EPILEPSY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; ANTICONVULSANTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; SEIZURES; SPASMS, INFANTILE; TRIAZOLES; VALPROIC ACID; YOUNG ADULT;

EID: 79953220728     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820fa9ad     Document Type: Article

References (25)

1. Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr. 2010;10:1-6.
2. Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome. Ann Pharmacother. 2010;44:658-667.
3. Ferrie CD. Rufinamide: a new antiepileptic drug treatment for Lennox- Gastaut syndrome. Expert Rev Neurother. 2010;10:851-860.
4. Hakimian S, Cheng-Hakimian A, Anderson GD, et al. Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother. 2007;8: 1931-1940. (Pubitemid 47321524)
5. Deeks ED, Scott LJ. Rufinamide. CNS Drugs. 2006;20:751-760; discussion 761. (Pubitemid 44373706)
6. Perucca E, Cloyd J, Critchley D, et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-1141. (Pubitemid 351991401)
7. Elger CE, Stefan H, Mann A, et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010;88:255-263.
8. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox- Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. March 1, 2010 [Epub ahead of print].
9. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17:546-548.
10. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14:491-495.
11. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009;50:1899-1909.
12. Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol. 2009;24:1520-1525.
13. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70: 1950-1958.
14. Palhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. 2001;43:115-124. (Pubitemid 32115522)
15. Cardot JM, Lecaillon JB, Czendlik C, et al. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos. 1998;19:259-262. (Pubitemid 28218421)
16. Liang K-L, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986:73:13-22.
17. Besag FMC, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000; 41:624-627. (Pubitemid 30253437)
18. May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999;21:175-181. (Pubitemid 29168895)
19. May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002;24:366-374. (Pubitemid 34553201)
20. May TW, Rambeck B, Jü rgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 2003;25:690-699. (Pubitemid 37499303)
21. May TW, Rambeck B, Neb R, et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29:789-794. (Pubitemid 350190856)
22. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007;48: 1351-1359. (Pubitemid 47063068)
23. Weintraub D, Buchsbaum R, Resor SR, et al. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62: 1432-1436. (Pubitemid 41352061)
24. Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342-348. (Pubitemid 41060254)
25. Brandt C, Baumann P, Eckermann G, et al. Therapeutic drug monitoring in epileptology and psychiatry. Nervenarzt. 2007;17:167-174.